Table 1 Clinical and pathological characteristics of STAD patients in the training and testing cohort.
Covariates | Type | Total | Testing | Training | p-value |
|---|---|---|---|---|---|
Age | <=65 | 183 (44.96%) | 60 (42.86%) | 123 (46.07%) | 0.5403 |
> 65 | 221 (54.3%) | 80 (57.14%) | 141 (52.81%) | ||
unknow | 3 (0.74%) | 0 (0%) | 3 (1.12%) | ||
Gender | FEMALE | 144 (35.38%) | 58 (41.43%) | 86 (32.21%) | 0.0821 |
MALE | 263 (64.62%) | 82 (58.57%) | 181 (67.79%) | ||
Grade | G1 | 12 (2.95%) | 5 (3.57%) | 7 (2.62%) | 0.8338 |
G2 | 144 (35.38%) | 48 (34.29%) | 96 (35.96%) | ||
G3 | 242 (59.46%) | 84 (60%) | 158 (59.18%) | ||
unknow | 9 (2.21%) | 3 (2.14%) | 6 (2.25%) | ||
Stage | Stage I | 55 (13.51%) | 18 (12.86%) | 37 (13.86%) | 0.9259 |
Stage II | 122 (29.98%) | 42 (30%) | 80 (29.96%) | ||
Stage III | 167 (41.03%) | 60 (42.86%) | 107 (40.07%) | ||
Stage IV | 39 (9.58%) | 12 (8.57%) | 27 (10.11%) | ||
unknow | 24 (5.9%) | 8 (5.71%) | 16 (5.99%) | ||
T | T1 | 21 (5.16%) | 6 (4.29%) | 15 (5.62%) | 0.916 |
T2 | 86 (21.13%) | 31 (22.14%) | 55 (20.6%) | ||
T3 | 179 (43.98%) | 62 (44.29%) | 117 (43.82%) | ||
T4 | 113 (27.76%) | 41 (29.29%) | 72 (26.97%) | ||
unknow | 8 (1.97%) | 0 (0%) | 8 (3%) | ||
M | M0 | 362 (88.94%) | 128 (91.43%) | 234 (87.64%) | 0.7941 |
M1 | 26 (6.39%) | 8 (5.71%) | 18 (6.74%) | ||
unknow | 19 (4.67%) | 4 (2.86%) | 15 (5.62%) | ||
N | N0 | 121 (29.73%) | 40 (28.57%) | 81 (30.34%) | 0.4947 |
N1 | 108 (26.54%) | 37 (26.43%) | 71 (26.59%) |
